Aytu Biopharma (AYTU) Common Equity (2011 - 2026)

Aytu Biopharma (AYTU) has 16 years of Common Equity data on file, last reported at $35.1 million in Q1 2026.

• Common Equity for Q1 2026 came in at $35.1 million, up 0.7% year-over-year; the trailing twelve-month figure through Mar 2026 was $35.1 million (up 0.7% YoY), and the FY2025 annual result was $19.0 million, down 31.57% from the prior year.
• Common Equity climbed to $35.1 million in Q1 2026 per AYTU's latest filing, from $14.2 million in the prior quarter.
• Over five years, Common Equity peaked at $61.1 million in Q1 2022 and troughed at $14.2 million in Q4 2025.
• A 5-year average of $34.7 million and a median of $32.9 million in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2025: Common Equity slumped 67.79% in 2022, then increased 13.39% in 2025.
• A 5-year view of Common Equity shows it stood at $45.8 million in 2022, then fell by 28.3% to $32.9 million in 2023, then fell by 6.36% to $30.8 million in 2024, then tumbled by 53.84% to $14.2 million in 2025, then jumped by 147.47% to $35.1 million in 2026.
• Business Quant data shows AYTU's Common Equity at $35.1 million in Q1 2026, $14.2 million in Q4 2025, and $23.2 million in Q3 2025.